Sleep Apnea
60 articles on Sleep Apnea, researched and written by the Shotlee Editorial Team from primary sources.
The Billion-Dollar Problem Limiting Access to Ozempic, Wegovy, and Zepbound
Despite clinical evidence highlighting the significant health benefits and cost-effectiveness of GLP-1 medications such as Ozempic, Wegovy, and Zepbound, many insurance plans continue to impose restrictions on patient access. This article delves into the financial and practical barriers, as well as the profound consequences for individuals seeking these transformative treatments.
7 min read
Katie Lee Biegel Shares Update on 'Incredibly Positive' GLP-1 Experience
Food Network personality Katie Lee Biegel opens up about her journey with GLP-1 medications, detailing her 'incredibly positive' experience with weight loss and enhanced well-being.
10 min read
Eli Lilly to Seek FDA Approval for Obesity Drug Retatrutide
Eli Lilly announces plans to file for FDA approval of its triple-agonist obesity drug retatrutide in early 2027 following successful Phase 3 trial data.
8 min read
GLP-1s for Teen Weight Loss: A New Treatment Trend?
GLP-1 medications are rapidly changing obesity care for teens and young adults, with a notable shift away from bariatric surgery. This article delves into the latest research, potential benefits, and important considerations for this emerging trend.
7 min read
Medicare's New GLP-1 Weight-Loss Drug Program: What to Know
Medicare is launching a new pilot program to increase access to GLP-1 medications for weight loss, offering a $50 monthly copay for eligible beneficiaries. This marks a significant step in covering obesity as a medical condition.
9 min read
Semaglutide (Ozempic, Wegovy) Offers Heart Protection Beyond Weight Loss
A groundbreaking study published in The Lancet demonstrates that semaglutide, the active ingredient in Ozempic and Wegovy, provides substantial cardiovascular protection independent of the amount of weight lost. This finding reshapes our understanding of how these GLP-1 receptor agonists benefit heart health.
7 min read
Beyond the Hype: Understanding GLP-1s and Weight Management
The rise of GLP-1 medications has revolutionized weight management. This comprehensive guide delves into semaglutide, tirzepatide, and other peptide therapies, offering insights into their efficacy, potential side effects, and how to track your progress effectively.
7 min read
Medicare's $50 GLP-1 Weight Loss Drug Trial: Who Qualifies?
For many older Americans, the high cost of GLP-1 weight loss medications has been a significant barrier. Now, a new Medicare trial offers a lifeline, potentially making these life-changing drugs accessible for just $50 a month. This article breaks down what you need to know about the Medicare GLP-1 Bridge program, including who qualifies, which medications are covered, and the program's future.
8 min read
Ozempic, Wegovy, Mounjaro: The GLP-1 Revolution in Weight Loss
A closer look at the groundbreaking GLP-1 medications, including Ozempic, Wegovy, and Mounjaro, and their transformative effects on weight management and overall health.
6 min read
Medicare's GLP-1 Weight Loss Drug Bridge: What You Need to Know
For the first time, Medicare is expanding access to GLP-1 medications for weight loss through a new pilot program. Starting July 1, eligible beneficiaries can access popular drugs like Wegovy and Zepbound for a $50 monthly copay. This groundbreaking initiative aims to make these life-changing treatments more accessible, but understanding the specifics is crucial.
7 min read
Beyond the Scale: Navigating GLP-1s for Older Adults
As GLP-1 medications become more accessible, older adults are asking: 'Am I too old?' This guide explores the nuances of using these powerful drugs for weight loss in seniors, emphasizing health over age.
7 min read
Wegovy Arrives in Jordan: A New Era for Weight Management
Novo Nordisk has officially launched Wegovy®️ (semaglutide 2.4 mg) in Jordan, marking a significant advancement in the country's approach to tackling the growing challenge of excess weight and its associated health risks.
7 min read
Ozempic, Wegovy, Mounjaro: Navigating the New GLP-1 Landscape
The landscape of GLP-1 medications for weight loss and chronic disease management is rapidly evolving. From new access programs to shifting pricing dynamics, understanding these advancements is crucial for patients and healthcare providers alike.
6 min read
Ozempic Culture: Why Medical Weight Loss Needs Better Guardrails
As semaglutide medications become ubiquitous, we must balance their life-saving cardiovascular benefits with the dangers of normalizing extreme thinness and disordered eating behaviors.
7 min read
Beyond the Hype: Navigating GLP-1s for Sustainable Health
As demand for GLP-1 medications soars, healthcare professionals emphasize a balanced, comprehensive approach to weight management and chronic disease treatment, focusing on sustainability and patient well-being.
7 min read
Zepbound vs. Wegovy: New Meta-Analysis Reveals Top Weight Loss Drug
A comprehensive meta-analysis from the University of Georgia has finally put major weight loss medications head-to-head. Here is what the data says about Zepbound, Wegovy, and Saxenda.
8 min read
Beyond Ozempic: Why Zepbound Might Be the Heavyweight Champion for Weight Loss
A comprehensive review of the latest clinical data comparing Tirzepatide, Semaglutide, and Liraglutide to determine the most effective option for significant weight reduction.
8 min read
Ozempic and Testosterone: Does Weight Loss Drive Sperm Quality Gains?
A comprehensive review of clinical trials suggests that GLP-1 medications may offer reproductive benefits for men with obesity-related low testosterone, potentially surpassing traditional hormone replacement therapies.
7 min read
Ozempic and Male Fertility: Can Semaglutide Boost Sperm Quality?
Emerging research indicates that GLP-1 medications, including Ozempic and Mounjaro, may offer unexpected benefits for male reproductive health by addressing underlying metabolic issues.
7 min read
Beyond Weight Loss: How GLP-1s Impact Your Blood Pressure
GLP-1 receptor agonists, known for their role in diabetes and weight management, are increasingly recognized for their broader health benefits, including effects on blood pressure. This article delves into how these medications work, their impact on cardiovascular health, and whether they are safe for individuals with hypertension.
8 min read
Ozempic, Wegovy, Mounjaro: Why Rhode Island Medicaid Must Cover Obesity Meds
Rhode Island's strategic health initiatives are commendable, but a recent budget proposal to cut Medicaid coverage for GLP-1 obesity treatments like Ozempic and Wegovy raises serious concerns. This decision, while seemingly a cost-saving measure, risks long-term health consequences and increased healthcare expenditures.
6 min read
Retatrutide Phase 3 Results: 28% Weight Loss and the Triple Agonist Promise
Eli Lilly has released pivotal Phase 3 trial data for retatrutide, a triple agonist showing up to 28% body weight reduction and significant improvements in diabetes and sleep apnea.
7 min read
GLP-1s and Alzheimer's: Hope, Hype, and the Science of Prevention
GLP-1 receptor agonists are showing promise for brain health by reducing inflammation, but experts caution that using these powerful medications solely for dementia prevention is premature, especially given mixed clinical trial results.
6 min read
Beyond Weight Loss: The Expanding Horizon of GLP-1 Therapies
GLP-1 agonists, famously known for Ozempic and Wegovy, are making waves beyond their initial indications. While weight loss and diabetes management remain key, researchers are uncovering a broader therapeutic potential for these powerful peptide therapies.
8 min read
Beyond BMI: Why Mounjaro Eligibility is More Complex Than You Think
Many assume BMI is the sole determinant for Mounjaro prescriptions, but the reality is far more nuanced. This article explores the comprehensive health criteria healthcare providers use to ensure safe and effective treatment.
6 min read
Wegovy Pill Nears EU Approval: A New Era for Obesity Treatment?
Novo Nordisk's groundbreaking Wegovy pill has received a significant recommendation for approval from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP). This marks a pivotal step towards potentially broadening access to advanced weight management solutions for adults across the European Union.
6 min read
Beyond the Hype: How GLP-1s Like Wegovy Are Reshaping Retail Spending
The growing popularity of GLP-1 medications, including Wegovy, is having a notable impact on retail spending, particularly in the pharmaceutical sector. This article delves into the economic implications and what it means for consumers and businesses.
6 min read
Driving on Ozempic & Mounjaro: Avoiding the £1,000 DVLA Fine
New regulations warn that GLP-1 medication users could face significant fines if side effects impair driving. Here is the complete guide to staying safe and compliant.
8 min read
Retatrutide's Triumph: Lilly's Triple Agonist Redefines Weight Loss Potential
Eli Lilly's retatrutide is making waves in the weight loss landscape. This comprehensive look delves into its Phase III results, comparing it to existing treatments and exploring its potential impact on obesity management.
6 min read
Beyond Willpower: Understanding Obesity's Metabolic Roots
Obesity is a complex, multi-organ disease, not a failure of willpower. This article delves into its metabolic underpinnings and outlines a practical approach to management, including modern medications and lifestyle adjustments.
7 min read
GLP-1s for Weight Loss: The NHS Two-Year Limit & Private Costs
As GLP-1 agonists revolutionize weight management, many patients face a critical juncture when NHS funding ends. This article delves into the realities of these powerful medications, the challenges of long-term access, and the growing divide between publicly funded care and private treatment costs.
7 min read
Pharmac Funding for Wegovy: What NZ Patients Need to Know
New Zealand's Pharmac funding agency has moved semaglutide (Wegovy) to its investment list. Here is what this means for eligibility, costs, and access.
8 min read
PCOS Renamed PMOS: A New Era for Endocrine Health
Polycystic Ovary Syndrome (PCOS), a condition affecting millions of women, is undergoing a significant renaming to Polyendocrine Metabolic Ovarian Syndrome (PMOS). This change aims to better reflect the condition's complex interplay with endocrine and metabolic systems, potentially improving diagnosis and treatment.
8 min read
GLP-1 Overdose Leads to Severe Diarrhea: A Warning
A man's harrowing experience with extreme diarrhea after overdosing on an experimental GLP-1 drug, retatrutide, serves as a stark reminder of the risks associated with obtaining and using unapproved medications outside of medical supervision. This article delves into the case, the science behind these powerful weight loss drugs, and the importance of regulated healthcare.
7 min read
GLP-1 Pills for Weight Loss: 8 Key Insights Before You Begin
GLP-1 medications are now available as pills for weight loss, offering a needle-free alternative. This comprehensive guide explores what you need to know before starting, including efficacy, absorption, side effects, and lifestyle considerations.
12 min read
Online GLP-1 Programs: Revolutionizing Medically Supervised Weight Loss
Discover the seismic shift in obesity medicine as online GLP-1 programs leverage telehealth and advanced medications like semaglutide and tirzepatide to provide accessible, medically supervised weight loss solutions.
11 min read
GLP-1 Weight Loss Drugs: The Hidden Social Cost of Success
While GLP-1 medications offer a powerful new path to weight loss, emerging research reveals an unexpected challenge: intensified social stigma. This article explores the nuances of this phenomenon and its implications for patients.
7 min read
GLP-1 Drugs vs. Weight Loss Surgery: A Shifting Landscape
New research indicates a significant decline in bariatric surgeries, coinciding with the rise of GLP-1 medications. This article delves into the implications, comparing the efficacy and cost-effectiveness of these treatments and offering guidance for patients.
7 min read
Unexpected Discoveries: How Failed Drugs Became Medical Breakthroughs
Discover how serendipity and keen observation transformed drug development, leading to life-changing treatments for conditions ranging from diabetes and obesity to erectile dysfunction and wrinkles.
6 min read
GLP-1 Drugs & Your Health: Beyond Weight Loss & 'Ozempic Breath'
GLP-1 agonists are revolutionizing weight management, but their effects extend far beyond the scale. This article delves into the science, the side effects like 'Ozempic breath,' and how these powerful medications are reshaping consumer habits and personal health journeys.
7 min read
New Procedure May Combat Weight Regain After GLP-1s
Losing weight with GLP-1 medications like semaglutide and tirzepatide is a significant achievement, but maintaining that loss after stopping treatment presents a major challenge. A new experimental procedure, duodenal mucosal resurfacing (DMR), is showing remarkable potential in helping individuals keep the pounds off.
7 min read
GLP-1 Medications & Weight Loss: What's Behind the Buzz?
The world of weight management has been significantly impacted by the emergence of GLP-1 receptor agonists. These medications, including popular drugs like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro), have garnered immense attention for their effectiveness in promoting weight loss and improving metabolic health. But what exactly are these drugs, how do they work, and what should individuals considering them know?
7 min read
Semaglutide NAION Risk: New Study Findings for Weight Loss Patients
A recent analysis published in JAMA Ophthalmology reveals a significant increase in NAION risk associated with semaglutide compared to SGLT2 inhibitors, though absolute risk remains low.
8 min read
Medicare Expands GLP-1 Coverage: What the 2027 Policy Shift Means for Seniors
The federal government has extended its commitment to fund GLP-1 obesity medications through 2027, shifting away from private insurer mandates to protect seniors from premium hikes.
2 min read
Tirzepatide vs. Semaglutide: A Comprehensive Guide to Cost and Health Outcomes
A new lifetime economic analysis suggests tirzepatide may offer superior long-term value and clinical outcomes compared to semaglutide for obesity management.
2 min read
Obesity Drug Coverage Restrictions Force Patients to Pivot
For Meghan Lena, losing coverage for Zepbound felt devastating after losing 50 pounds. Now, GoodRx reports 12 million people will lose access to Zepbound and Wegovy from 2025-2026 due to insurance changes. Patients are pivoting to alternatives amid rising restrictions and costs.
8 min read
Luke Combs Rejects GLP-1 for Weight Loss: 'Not the Short Way'
Country music sensation Luke Combs is turning down GLP-1 medications for weight loss, opting for the hard road instead. In a candid New York Times interview, he shares fears about his appearance affecting his career and why 'that stuff scares me more than the benefits.' This stance highlights debates around quick fixes versus lifelong habits in weight management.
4 min read
GLP-1s Aid Health Even Without Weight Loss: New Evidence
While most people on GLP-1 medications like Wegovy experience significant weight loss, 10-15% are non-responders. Emerging research shows these drugs still improve liver health, reduce heart risks, and more—independent of weight changes. A new mouse study reveals why, challenging insurance requirements for weight loss thresholds.
5 min read
India's GLP-1 Opportunity: Startups Betting Big on Weight Loss
With semaglutide's patent expired in India, over 50 generic brands are flooding the market at competitive prices, fueling a five-fold GLP-1 expansion to ₹5,000 crore by 2030. Startups like HealthifyRx, VLCC, Sugarfit, and FITPASS are redefining weight loss with holistic programs combining drugs, coaching, and muscle preservation. Investors warn that only comprehensive care models will thrive amid rising competition.
6 min read
GLP-1s Benefit Non-Responders Without Weight Loss: New Evidence
While most people on GLP-1 medications like Wegovy experience dramatic weight loss, 10-15% are non-responders. Emerging research shows these drugs still deliver benefits for liver disease, heart health, and more—independent of the scale. A new study from Dr. Daniel Drucker's lab uncovers why.
5 min read
Study: Semaglutide Does Not Raise NAION Risk in Obesity, Diabetes
A large study presented in San Diego reveals semaglutide use is not associated with higher risk of non-arteritic anterior ischemic optic neuropathy (NAION) in patients with overweight or obesity. In fact, it lowered NAION risk by 64% among those with type 2 diabetes compared to non-GLP-1 therapies. Experts emphasize continued monitoring of blood sugar and blood pressure.
5 min read
FDA Approves Foundayo Weight Loss Pill, Igniting GLP-1 Showdown
The FDA has approved Foundayo weight loss pill from Eli Lilly on April 1 (ET), introducing a flexible oral GLP-1 option for adults with obesity or weight-related conditions—no food or water restrictions needed. Trial data shows superior weight loss over Rybelsus, averaging 15-20 pounds vs. 8-11 pounds in diabetes patients. This approval sets up a new showdown in the GLP-1 market dominated by injections like Wegovy and Zepbound.
5 min read
India's 'Mounjaro Brides': Weight-Loss Injections in Pre-Wedding Prep
In India, 'Mounjaro brides' are using weight-loss injections as part of pre-wedding rituals, driven by intense societal expectations. Clinics like Klarity Skin Clinic offer specialized packages, while doctors report a surge in queries from brides and grooms. This trend highlights both the drugs' popularity and the need for medical supervision.
5 min read
Wegovy's New Subscription Saves Up to $1,200/Year – Not for Everyone
Novo Nordisk has launched a new subscription program for Wegovy, promising up to $1,200 in yearly savings on injections to help patients maintain access to this GLP-1 obesity drug. With plans starting at $249 per month for 12 months, it targets self-pay users facing cost uncertainty. But eligibility limits mean it's not for everyone—here's what you need to know.
4 min read
Wegovy Linked to Sudden Vision Loss Risk, Study Finds
Researchers analyzing over 30 million FDA safety reports found Wegovy associated with nearly five times higher odds of ischemic optic neuropathy (ION), or 'eye stroke,' compared to Ozempic. This sudden vision loss risk was strongest in men on Wegovy. While rare, these findings urge caution and further study for GLP-1 users.
5 min read
Experts Stress Holistic Approach to Semaglutide for Weight Management
At a recent Pune meeting, experts from Pune and Mumbai underscored a holistic framework for Semaglutide use in weight management, especially as the drug goes off-patent in India. They stress pairing it with diet, exercise, and thorough patient assessments for lasting results in obesity and diabetes control. Generic versions now available for Rs 1,290 per month offer affordable access with proper precautions.
6 min read
GLP-1 Discontinuation: Mixed Weight Loss Results in Real-World Study
A large real-world study from Cleveland Clinic reveals mixed outcomes after GLP-1 discontinuation: 55% of obese patients regained weight, while 45% maintained or continued losing. Many switched to alternative treatments, highlighting the need for ongoing obesity care. This data underscores gaps in long-term management and the role of nutritional support.
5 min read
Study: Wegovy Vision Loss Risk 5x Higher Than Ozempic
A groundbreaking study reveals Wegovy carries a fivefold higher risk of vision-threatening ischemic optic neuropathy compared to Ozempic. Analyzing millions of FDA reports, researchers link the risk to semaglutide's higher doses in Wegovy. Amid rising lawsuits, patients need to weigh benefits against potential eye health dangers.
5 min read
Could Ozempic and GLP-1s Help ADHD Symptoms?
People with ADHD report feeling calmer and more focused on GLP-1 drugs like Ozempic, originally for obesity and diabetes. Experts explain potential links to dopamine and reduced food cravings, but stress no clinical trials prove direct benefits. Find out the real story behind social media buzz and what to discuss with your doctor.
5 min read
Amazon Pharmacy Adds Zepbound KwikPen to Same-Day Delivery
Amazon Pharmacy is streamlining GLP-1 access by adding Zepbound KwikPen to its same-day delivery service. This multi-dose device holds a full month's supply, addressing manufacturing bottlenecks and offering $299 cash-pay pricing—far below traditional $1,000 quotes. Integrated with Amazon One Medical, it provides personalized care for weight management and obstructive sleep apnea patients.
4 min read